A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
The study consists of Screening, Treatment, and Follow-up periods.
Key Inclusion criteria:
Participant is an adult, male or female ≥ 18 years of age at the time of informed consent form signature (IC).
Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer (BC) based on the most recently analyzed tissue sample tested by a local laboratory prior to enrollment.
Participant has HER2- BC defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing based on the most recently analyzed tissue sample.
Participants may have already received any standard neoadjuvant and/or adjuvant ET, including tamoxifen or toremifene at the time of informed consent signature, but enrollment should occur within 36 months of prior ET start date and participants should have at least 3 years remaining of endocrine adjuvant therapy.
For participants with prior ET treatment > 12 months, restaging is highly recommended (unless contradictory to local regulations) to rule out disease recurrence prior to enrollment.
The number of participants with prior ET between 12 and 36 months will be capped at 30%. The cap will not apply to Black or African American participants.
Participant has no contraindication to receive adjuvant ET in the study.
Participant after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories:
Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
Participant has adequate bone marrow and organ function.
ECG values assessed by KardiaMobile-6L device, or standard 12-lead ECG per local investigator where KardiaMobile-6L cannot be used, as:
Key Exclusion criteria:
Other inclusion/exclusion criteria may apply
novartis.email@novartis.com1-888-669-6682
novartis.email@novartis.com+41613241111
Birmingham, Alabama 35209, United States
LSzymela@centralalabamaresearch.com
Washington D.C., District of Columbia 20007-2197, United States
Washington D.C., District of Columbia 20010, United States
Caba, Buenos Aires C1426ANZ, Argentina
Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
Weiden in Der Oberpfalz, Bavaria 92637, Germany
Bergisch Gladbach, North Rhine-Westphalia 51465, Germany
Mönchengladbach, North Rhine-Westphalia 41061, Germany
Hyderabad, Andhra Pradesh 500034, India
New Delhi, National Capital Territory of Delhi 110029, India
Alc Cuahutemoc, Mexico City 06720, Mexico
Bundang Gu, Gyeonggi-do 13620, South Korea
Seongnam Gyeonggi, 463-712, South Korea
Kecioren Ankara, 06010, Turkey (Türkiye)
talia@alaskaoncology.com907-279-3155
ssheerinfadden@coh.org623-207-3381
Emily.Johnson@carti.com501-906-3000
ocanlas@bhcancercenter.com310-432-8900
sabrina.mora@heliosclinical.com562-698-6888
flewis@coh.org+1 6263598111#65994
teresa.olea@stjoe.org714-449-6200
tannya.lovato@lahomg.com213-977-1214
zoe_higgins@elcaminohealth.org
christine.lee4@sutterhealth.org650-853-5763
ruizs11@hs.uci.edu714-456-6288
dunncm@sutterhealth.org916-453-5742
avorasaph@health.ucdavis.edu
danica.griffin@sharp.com
Melanie.Burland@adventhealth.com
maria.saucedo1@usoncology.com303-321-0302
bickmorj@georgetown.edu202-687-8676
kidist.t.dugassa@medstar.net202-877-2146
rebecca.iorio@adventhealth.com
Eileen.Georgi@holy-cross.com954-771-8000
kfundora@bioresearchpartner.com
fbrunengo@mhs.net
christine.leonard@jupitermed.com561-263-5768
Michelle.Jackson@usoncology.com352-351-7126
npope@universitycancer.com
twilliams@summitcancercare.com
AngeleiJan.Gommesen@aoncology.com
angela.malone@usoncology.com
kkolluri@hopenheal.care
aamoabin@coh.org847-872-4561
zedgell@investigativeicr.com
tcaon@missioncancer.com
ccupp@kumc.edu
Alexandre.Khoury@cancercenterofkansas.com316-262-4467
bbarrow@wkhs.com
acline@mdmercy.com+1 410 332 1200
teresa.saavedra@usoncology.com
tara.hassanigoodarzi@bmc.org
lauryn_vassel@dfci.harvard.edu617-632-5607
laurae_melancon@dfci.harvard.edu617-732-9850
Anne.rabenn@usoncology.com
jonathan.alexander@allina.com612-863-9466
tdavis@jacksononcology.com601-974-5547
katherine.burnside@hcahealthcare.com
ainsworth@wustl.edu314-747-8085
kelsi.margaris@imail.org
hcordes@nebraskacancer.com+1 402 334 4773
Bayley.Stoner@renown.org
Lquinonez@ccsreno.com
patel-naimik@cooperhealth.edu
mkurt4@summithealth.com973-538-5210
eclark2@valleyhealth.com
mrobertso2@phs.org505-559-6100
buLoneL@nychhc.org718-883-3751
rabia.khan2@uhn.ca+1 516 488 2918#183
weronika.bucwinska@mssm.edu
catrin.davies@duke.edu
Nikki.Eldreth@conehealth.com336-832-1100
angela.bruns@sanfordhealth.org701-234-2371
evantil@samhealth.org541-768-5800
Spencer.dandy@usoncology.com
Heather.Firneisz@usoncology.com971-708-7600
kkinney@orcancer.com
maureen.Lisowski@usoncology.com
cookhm2@upmc.edu717-652-3000
sarah.montini@ahn.org
jgrigelevich@brownhealth.org401-444-7525
Christine_Sanchez@bshsi.org+1 864 603 6214
jane.veerman@sanfordhealth.org605-328-8000
madeleine.enos@scri.com615-329-7270
mary.williams2@usoncology.com
shawndra.alexander@kelseyresearch.com713-442-1224
ctamez@mdanderson.org713-794-5783
Kristy.Dillard@usoncology.com972-867-3577
jennifer.castner@usoncology.com
Mary_Williams7@bshsi.org804-894-8665
Derek.Varner@usoncology.com
heather.e.harris@kadlec.org509-783-0144
deidre.dillon@providence.org360-754-3934
Dione_Froman@valleymed.org
pwalsh@nwmsonline.com253-428-8756
mapps@mcw.edu414-805-5249
nathalia.verge@panoncologytrials.com+1 787 407 3333